Data collection method and kit for determining likelihood of developing alzheimer's disease

Abstract

A data collection method for determining the likelihood that a subject will develop AD that includes measurement of methylation levels in the CpG regions of promoter regions, untranslated regions or translated regions of specific genes in biological samples from subjects, wherein higher or lower methylation levels compared with NCs indicate that a subject is at risk of developing AD.

1 . A data collection method for determining the likelihood that a subject will develop AD that includes measuring the percentage of DNA methylation in biological samples from subjects in CpG regions of promoter regions, untranslated regions or translated regions of at least one gene selected from groups consisting of the following, wherein higher or lower methylation levels compared with NCs indicate that a subject is at risk of developing AD: ELOVL2, OLIG3, SLC7A14, ACTA1, SOX17, DPYS, LOC728661, CDK11B, NEFM, SMTN, GDF15, RUNX3, PPP1R14A, ZNF75A, C4orf41, RWDD4A, ADAM12, PENK, TBX15, GREM1, KIAA0895L, EXOC3L, TM6SF2, CSNK1G2, FAM53A, DOCK1, FAM196A, WDR81, TCEA2, C3orf26, FILIP1L, MIR548G, CCDC28A, NPY1R, KIAA0182, MARCH1, XPNPEP3, ST13, FAM5B, TCP11, SLC25A2, ZNF415, PCDH8, TIMM44, CTXN1, HIST1H3D, HIST1H2BF, HIST1H2AD, RBMXL3, LRCH2, LOXL1, SLC34A2, RASGRP2, PCDHB7, SLC12A8, KANK1, ALPK3, FARP1, WDR17, GNAS, GNASAS, SOLH, ATL2, PCDHB10, PDE4C, NKAIN3, GABRA2, PCDHA2, PCDHA1, PCDHA3, PCDHA4, PCDHA5, FZD9, ATP5SL, PCDHB4, PRR23A, ADC, ABCA1, L3MBTL4, TSSK6, PCDHA6, ANKRD45, FAM163A, ESRRA, PEAR1, IRS2, GFI1, KCTD1, FGR, LOC100130691, AGPS, CSNK1G1, APAF1, IKBIP, PRIC285, ZBTB7B, TEF, EGLN2, LMBR1L, C19orf39, MEA1, KLHDC3, RHPN1, C8orf51, FLCN, PQLC1, TRIM23, C5orf44, PRR3, GNL1, PYCR1, SPTBN4, BLVRB, BAZ1A, ZFHX3, SLC25A46, RBM14, HNRNPC, HDAC11, SLC16A14, C4orf33, SCLT1, GPR68, HSPA8, ZSWIM7, TTC19, PRPF40B, RAB10, SLC37A1, AMD1, ANKLE2, CD55, SSBP4, MGC23284, SNA13, SMG1, APBB1IP, NDUFB1, CPSF2, MBTD1, UTP18, NPBWR2, RWDD2A, PGM3, MZF1, LOC100131691, C19orf12, LIN54, PHLDA2, SERINC5, MPV17L2, ZNF10, C3orf39, GPX1, TRPC4AP, REST and TBKBP1. 
     
     
         2 . Data collection method indicated in  claim 1 , wherein biological samples are blood. 
     
     
         3 . Kit for determining the likelihood that a subject will develop AD that includes primers or probes for amplifying DNA methylation regions in CpG regions of promoter regions, untranslated regions or translated regions of at least one gene selected from groups consisting of the following: ELOVL2, OLIG3, SLC7A14, ACTA1, SOX17, DPYS, LOC728661, CDK11B, NEFM, SMTN, GDF15, RUNX3, PPP1R14A, ZNF75A, C4orf41, RWDD4A, ADAM12, PENK, TBX15, GREM1, KIAA0895L, EXOC3L, TM6SF2, CSNK1G2, FAM53A, DOCK1, FAM196A, WDR81, TCEA2, C3orf26, FILIP1L, MIR548G, CCDC28A, NPY1R, KIAA0182, MARCH1, XPNPEP3, ST13, FAM5B, TCP11, SLC25A2, ZNF415, PCDH8, TIMM44, CTXN1, HIST1H3D, HIST1H2BF, HIST1H2AD, RBMXL3, LRCH2, LOXL1, SLC34A2, RASGRP2, PCDHB7, SLC12A8, KANK1, ALPK3, FARP1, WDR17, GNAS, GNASAS, SOLH, ATL2, PCDHB10, PDE4C, NKAIN3, GABRA2, PCDHA2, PCDHA1, PCDHA3, PCDHA4, PCDHA5, FZD9, ATP5SL, PCDHB4, PRR23A, ADC, ABCA1, L3MBTL4, TSSK6, PCDHA6, ANKRD45, FAM163A, ESRRA, PEAR1, IRS2, GFI1, KCTD1, FGR, LOC100130691, AGPS, CSNK1G1, APAF1, IKBIP, PRIC285, ZBTB7B, TEF, EGLN2, LMBR1L, C19orf39, MEA1, KLHDC3, RHPN1, C8orf51, FLCN, PQLC1, TRIM23, C5orf44, PRR3, GNL1, PYCR1, SPTBN4, BLVRB, BAZ1A, ZFHX3, SLC25A46, RBM14, HNRNPC, HDAC11, SLC16A14, C4orf33, SCLT1, GPR68, HSPA8, ZSWIM7, TTC19, PRPF40B, RAB10, SLC37A1, AMD1, ANKLE2, CD55, SSBP4, MGC23284, SNAI3, SMG1, APBB1IP, NDUFB1, CPSF2, MBTD1, UTP18, NPBWR2, RWDD2A, PGM3, MZF1, LOC100131691, C19orf12, LIN54, PHLDA2, SHRINC5, MPV1712, ZNF10, C3orf39, GPX1, TRPC4AP, REST and TBKBP1.